The immunovirological outcome of lopinavir/ritonavir was evaluated in 70 antiretroviral-experienced HIV patients; at baseline, median CD4+ cell count was 218 cells/mm3 and median plasma viraemia 4.58 log10 copies/mL. After 12 months, we observed an increase in CD4+ cell count to 322 cells/mm3 (P = 0.0001) and a decrease in plasma viraemia to 2.35 log10 copies/mL (P = 0.0001). Four patients discontinued lopinavir/ritonavir during observation. Among metabolic parameters, only triglyceride concentrations increased during treatment (P = 0.02). Twenty-six patients had a genotypic resistance test at baseline; four had ≥6 mutations known to reduce susceptibility to lopinavir/ritonavir. Undetectable plasma viraemia was obtained only in patients with ≤5 mutations (61.9%).
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: A retrospective cohort study / M. Bongiovanni, T. Bini, F. Tordato, P. Cicconi, S. Melzi, D. Repetto, S. Sollima, S. Rusconi, A. d'Arminio Monforte. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 51:1(2003), pp. 171-174.
|Titolo:||Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: A retrospective cohort study|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||2003|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1093/jac/dkg045|
|Appare nelle tipologie:||01 - Articolo su periodico|